




Innovating vaccines to reduce human disease

Michiel Stork, PhD
Vice President Business Development



Who we are

- Independent institute for vaccine development
 - Services from discovery to pilot production to clinical studies
 - The bridge between research and large-scale GMP manufacturing
 - ~30% of childhood vaccines are based on Bilthoven technology & know-how
 - Proprietary vaccine technology platforms
- Founded in 2013
 - 20 patent families
 - 132 skilled employees
 - State-of-the-art laboratory facilities (2000 m² R&D and 3 clean rooms)
 - 10 vaccine projects in development



Intravacc - Advancing Tomorrow's Vaccines

Our Vision

To reduce human disease through innovative vaccine technology

Our Mission

To partner with governmental agencies, NGOs and private entities to help to reduce burden of disease


The science
is in the
genes

The magic
is in the
knowledge

The art
is in the
execution

The fun
is in the
culture


Intravacc



Achievements and Track Record in Vaccine Development

- Global technology transfer of oral polio, measles, DPT, Hib and influenza vaccines
- Development of:
 - Sabin IPV vaccine (marketed by our partners)
 - nOPV2 strain and seed lot (vaccine approved for emergency use)
 - Hib conjugate vaccine (marketed by our partners)
 - Semi synthetic Shigella conjugate vaccine (Phase II ongoing)
 - Attenuated RSV vaccine (Phase I completed)
- Process development, formulation and manufacturing of diabetes type 1 vaccine
- Ongoing development with good pre-clinical results:
 - OMV-based Lyme vaccine
 - OMV-based COVID-19 vaccine
 - OMV based intranasal pertussis vaccine
 - OMV based gonorrhea vaccine
 - HFMD vaccine (multi-valent inactivated virus)
 - EVD68 vaccine (inactivated virus)

Intravacc's vaccine development platforms




Cell based viral platform

- Vero and HEK 293
- Viral (oncolytic, live attenuated and inactivated)
- Vector




OMV platform

- Bacterial
- Viral
- Adjuvant



iBoost

- Oncology
- Therapeutic



Conjugation

- Infectious disease
- Combination with OMV



Intravacc's product pipeline available for licensing and partnering

Vaccine	Target	Platform	Stage			
			Development	Pre-clinical	Phase I	Phase II
Avacc 19 [®]	RSV	Cell				
Avacc 10 [®]	Covid-19	OMV				
Avacc 3 [®]	Lyme	OMV				
Avacc 11 [®]	Gonorrhea	OMV				
Avacc 2 [®]	HFMD	Cell				
Avacc 5 [®]	EVD68	Cell				
Avacc 23 [®]	Bladder cancer	iBoost				

Corporate Overview

- **UNIQUE POSITION**

Intravacc is an independent vaccine development CDMO based in the Netherlands

- **EXTENSIVE TRACK RECORD**

High quality, good reputation, experts in vaccine development and technology transfer

- **DRIVING INNOVATION**

4 vaccine technology platforms to fast-track vaccine development

- **GMP**

Intravacc is well positioned to support vaccine concepts from discovery to pilot-scale GMP production

Intravacc would like to collaborate with you

Intravacc offers non-exclusive partnering opportunities for our technologies:

- OMV technology
- Vero cell technology
- iBoost technology
- Conjugation
- LPS (adjuvants)

Out-licensing of our products:

- COVID-19
- Lyme
- Gonorrhea
- HFMD
- EVD68
-



Corporate video



BD@intravacc.nl | +31 30 792 03 00

Utrecht Science Park Bilthoven
Antonie van Leeuwenhoeklaan 9
3721 MA Bilthoven

Visit intravacc.nl and follow us

